Amgen Responds To U.S. Appeals Court Decision to Reverse District Court Ban On Sales Of Sanofi/Regnereron's Praluent, Tells Benzinga: 'We are disappointed by the Court's action,' Ability To Deliver New Medicines Depends On 'Meaningful patent protection'